AUTHORS
Andrea Lang Goldgewicht, BA, Takahiro Ito, MD2, Shuichiro Takashima, MD3, Alexandre Albanese, PhD4, Marco Calafiore, PhD5, Anastasiya Ergorova6, Coco De Koning7, Marliek van Hoesel8, Masahiro Hirayama, MD, PhD9, Caroline Lindemans, MD, PhD10, Leslie Kean, MD, PhD11, Dietmar Martin Werner Zaiss, PhD12, Alan Hanash, MD, PhD13
AFFILIATIONS
1 Gerstner Sloan-Kettering Graduate School of Biomedical Sciences, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Mie University Graduate School of Medicine, Tsu, Japan
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Boston Children's Hospital, Boston, MA, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 University Medical Center Utrecht, Utrecht, Netherlands
8 University Medical Center Utrecht, Utrecht, Netherlands
9 Mie University Graduate School of Medicine, Tsu, Japan
10 Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, University Medical Center Utrecht, Utrecht, Netherlands
11 Boston Children's Hospital, Boston, MA, United States, Harvard Medical School, Boston, United States
12 Leibniz Institute for Immunotherapy, Regensburg, Germany, University Hospital Regensburg, Regensburg, Germany, University of Regensburg, Regensburg, Germany
13 Gerstner Sloan-Kettering Graduate School of Biomedical Sciences, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States, Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
ABSTRACT
Acute graft versus host disease (aGVHD) is a complication of allogeneic bone marrow transplant (allo-BMT) that can limit therapeutic success. Amphiregulin (Areg) is an EGFR ligand that is upregulated by Tregs, ILC2s, and other immune cells and can contribute to immune-mediated tissue regeneration (Arpaia et al. 2015; Monticelli et al. 2015). Although Areg has the potential to ameliorate tissue damage after aGVHD, it has also been shown to be elevated in the plasma of patients with aGVHD (Holtan et al. 2016), and the role of Areg expression in GVHD pathophysiology is unclear.
To assess the role of T cell-derived Areg in GVHD pathophysiology, we performed MHC-mismatched allo-BMT comparing Areg-intact (Aregfl/fl) and Areg-deficient (Aregfl/flxCD4-Cre) donor T cells. We observed that Areg was produced by donor CD4 T cells post-transplant and Areg deficiency led to improved survival and reduced GVHD histopathology in the liver and GI tract. Further, Areg deficiency reduced the infiltration of donor CD4 T cells in the spleen, mesenteric lymph nodes, and intestinal lamina propria early post BMT. Ex vivo analysis indicated that Areg promoted CD4 T cell proliferation and metabolic activity after activation, which could amplify the graft’s ability to induce aGVHD in this setting.
As aGVHD is primarily mediated by naive donor T cells in the graft that get activated post-transplant, we evaluated the contribution of Areg from this subset on aGVHD pathophysiology. We found that naive CD4 T cells expressed little Areg at baseline but progressively increased expression after ex-vivo activation. Comparing MHC-mismatched BMT with Areg-deficient versus Areg-intact naive donor CD4 T cells, we found that transplantation with Areg-intact naive donor CD4s resulted in rapid severe aGVHD. However, transplantation with Areg-deficient naive donor CD4 T cells resulted in reduced mortality, reduced systemic GVHD scoring, and reduced intestinal infiltration of TBET+ donor CD4 T cells in the lamina propria day 7 post-transplant.
As Areg can signal in a juxtacrine, autocrine, or paracrine manner, we evaluated which mechanism(s) contributed to CD4 T cell proliferation. Co-culture ex vivo or co-transfer in vivo with Areg-intact CD4 T cells failed to increase the expansion of Areg-deficient CD4 T cells, although these cells were capable of responding to exogenous recombinant Areg. ELISA performed using concentrated T cell culture media 72 hours after activation of Areg-intact vs. Areg-deficient T cells indicated low-level expression of secreted Areg after activation. Additionally, treatment with a metalloprotease inhibitor following T cell activation appeared to indicate Areg accumulation on the cell surface, further supporting Areg secretion by CD4 T cells after activation. Given the detection of secreted Areg at low concentrations and the lack of response to co-cultured/co-transferred T cells, Areg expression likely drove CD4 T cell proliferation via paracrine stimulation.
To evaluate the clinical relevance of our findings, we tested the Areg response of human CD4 T cells. Using cells derived from healthy volunteer PBMC samples, we confirmed AREG upregulation by flow cytometry after human CD4 T cell activation. Flow cytometry also indicated upregulation of its receptor, EGFR, upon human CD4 T cell activation. We also evaluated Day 28 Areg expression in CD4 T cells from a cohort of patients who underwent 8/8 MUD allo transplant using CNI/MTX for GVHD prophylaxis (n=66). A preliminary analysis of RNA sequencing indicated that Areg was elevated in CD4 T cells from patients with severe grade 3-4 aGVHD as compared to those with grade 0-2 GVHD (p<.001), indicating potential clinical relevance of CD4 T cell Areg expression.
In summary, we found that activation of naive CD4 T cells induces Areg production, which contributes to their metabolic activity and proliferation, leading to greater tissue infiltration and worsened GVHD severity following experimental allo-BMT. Human CD4 T cells also produced Areg after activation, and Areg expression by human CD4 T cells day 28 after clinical MUD allo-transplant correlated with GVHD severity. Therefore, rather than contributing to tissue repair, Areg expression by CD4 T cells was found to contribute to tissue damage post-transplant and worsened GVHD severity. Further investigation is necessary to determine how to manipulate the Areg/EGFR axis post-transplant for therapeutic benefit.
DISCLOSURES
Andrea Lang Goldgewicht, BA: No relevant conflicts of interest to declare.